HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and cross-border trading. We have established a "1+2+3+4=1" integrated service system and can supply beta-carotene sourced directly from multiple well-known original manufacturers. Equipped with independent R&D capabilities as a tech-driven foreign trade enterprise, HiSiaddi has conducted multiple rounds of factory inspections of beta-carotene manufacturers through technology transformation cooperation, accumulating objective and in-depth understanding of different brands. We regularly analyze various beta-carotene manufacturers for clients to help them select matching products. Below is a brand recommendation case.
For inquiries about brand and model comparative analysis, please contact HiSiaddi customer service.
The cooperating purchasing party in this project is BRITWELL NUTRITION, a premium nutrition group headquartered in London, UK. Founded 28 years ago, it specializes in high-end hospital dietary supplements and organic oral nutritional products sold across the UK mainland, Ireland and Wales. Its products are available in premium pharmacy counters of Boots UK, premium zones of Whole Foods national organic supermarkets and ophthalmology nutrition kits in private hospitals, complying with EU Regulation EC1333/2008 on food additives, European Pharmacopoeia standards, BRCGS UK food safety system, KOSHER certification and NOP non-GMO certification. The brand eliminates synthetic beta-carotene entirely and exclusively purchases naturally fermented Blakeslea trispora-grade raw materials, with core product lines covering eye-protecting soft capsules, sustained-release tablets and ambient functional oral liquids. Its stable annual procurement volume of natural beta-carotene totals 29 tons, distinguishing it from low-end buyers purchasing bulk low-cost feed-grade and general food-grade raw materials.
Previously, the brand sourced beta-carotene from DSM of the Netherlands. Plagued by rising domestic raw material prices in Europe and extended delivery lead times up to 75 days, it launched a China-based raw material supply chain development project in 2025, planning to selectively replace partial imported raw materials with domestic leading Chinese brands. The client independently contacted five leading domestic beta-carotene manufacturers: Dalian InnoBio, Wuhan Jiahua, Xi’an Haisifu, Zhejiang Medicine and Shandong Tianli Pharmaceutical. After one-on-one communication with manufacturer sales teams, the client fell into a product selection dilemma: sales representatives of each manufacturer only highlighted advantages of their own products and pushed their full product ranges, abiding by industry tacit agreements not to slander competitors, yet all avoided objective explanations of technical characteristics, product shortcomings and applicable scenarios of rival brands. The client only received one-sided product introductions, lacking horizontal objective data comparison to distinguish formula differences, stability gaps and terminal adaptability of over a dozen mainstream models across the five brands. After collecting samples from all five manufacturers, small-batch production trials on its production line successively exposed three differentiated issues: oil seepage during soft capsule storage, discoloration of tablets under accelerated testing and low-temperature delamination of oral liquids. The client could not determine whether the failures stemmed from incorrect raw material model selection or mismatched brand processes, incurring over GBP 72,000 in losses from sample testing, labor and production line debugging, halting new product progress for 45 days with no finalized procurement target. Ultimately, the client fully entrusted HiSiaddi to conduct neutral full-brand evaluation, horizontal comparison and precise product selection.
Mandatory product selection standards for the client’s three application scenarios: 30% oil suspension for soft capsules, 20% water-soluble microcapsule powder for tableting and 5% nano cold-soluble micropowder for oral liquids; all products required natural fermentation origin, no artificial synthetic antioxidants, ≥92% all-trans beta-carotene, and compliance with EU clean label regulations.
All five leading domestic beta-carotene manufacturers possess large-scale fermented mass production capacity with differentiated proprietary technical tracks, yet constrained by corporate operation orientations and sales assessment mechanisms, they universally prioritize promoting their own products over objective analysis of competitors, an industry-wide status quo with three root causes:
1. Sales performance and commission are solely tied to in-house product order volume, eliminating commercial incentives to proactively share technical highlights and applicable advantages of competing brands. Sales teams only briefly mention rival products when directly questioned, avoiding detailed parameter comparison of competing models.
2. Differentiated brand technical routes: Each manufacturer focuses R&D and quality control solely on its own product lines, lacking systematic measured data to horizontally dissect rival strengths and weaknesses: Jiahua prioritizes infant formula and patented microcapsule encapsulation products; Dalian InnoBio specializes in oil suspension technology; Haisifu focuses on nano cold-soluble formulations; Zhejiang Medicine leads in high-purity crystal raw materials; Shandong Tianli Pharmaceutical centers on cost-effective bulk mass-produced products.
3. The client lacks reserves of domestic industry information and authoritative third-party reference data. As a brand deeply rooted in the European dietary market, it is entirely unfamiliar with factory establishment backgrounds, patented technologies, segmented models and terminal application cases of domestic brands. No neutral selection handbook for domestic beta-carotene is publicly available, making model mismatch highly likely when relying solely on unilateral manufacturer introductions.
Given the above challenges, the client struggled to independently screen raw materials matching its three dosage forms, urgently requiring HiSiaddi to break information silos between manufacturers as a neutral third-party foreign trade service provider and horizontally dissect the full product range of the five brands.
HiSiaddi set up a three-person special team consisting of raw material technical engineers, foreign trade product selection specialists and EU compliance specialists. The team accessed official product manuals, third-party SGS test reports and terminal application measured data of the five brands, combining the client’s three terminal production processes for soft capsules, tablets and oral liquids to neutrally dissect brand positioning, core technologies, mainstream models, applicable scenarios and product shortcomings of Dalian InnoBio, Wuhan Jiahua, Xi’an Haisifu, Zhejiang Medicine and Shandong Tianli Pharmaceutical, fully recording pros and cons of each brand to break one-sided information barriers of individual manufacturers:
Brand strengths: The first domestic manufacturer certified under EU Novel Food and US FDA GRAS standards, holding six invention patents for fermentation and microcapsule encapsulation; full-line closed aseptic fermentation with complete raw material traceability systems; wall material formulas predominantly compounded with whey protein for superior powder flowability, targeting high-end infant formula and sustained-release tablet markets. Mainstream models: 20% microcapsule powder (tableting-specific CWS grade), 30% oil suspension (soft capsule-specific), 5% emulsified micropowder (oral liquid), 96% high-purity crystals. Product shortcomings: Limited mass production capacity for nano cold-soluble models; high quotation for small-batch customization; bulk delivery schedules constrained by infant formula order backlogs.
Brand strengths: Self-developed patented oil suspension technology with multiple optional carrier oils for 30% oil suspensions including sunflower oil and medium-chain oil; flexible natural extract antioxidant system replacement options; industry-leading storage stability of soft capsule raw materials with abundant supporting case studies for European dietary brands. Mainstream models: 30% non-GMO sunflower oil-based oil suspension, 20% general microcapsule granules, 1% low-content powder. Product shortcomings: Weak technical reserves for cold-water instant nano micropowder; limited range of oral liquid-specific models; high-purity crystal products are non-core product lines.
Brand strengths: Self-developed VegeLipi double-layer encapsulation and nano homogenization technology; 5% cold-soluble micropowder with particle size <200 nm and outstanding low-temperature storage stability, highly compatible with transparent oral liquids and functional beverages; proprietary strain library with intelligent oxygen control throughout fermentation and excellent impurity control. Mainstream models: 5% nano cold-soluble micropowder, 20% general microcapsules, 30% mineral oil-based oil suspension, NutraColour® high-purity crystals. Product shortcomings: Few tableting-specific microcapsule models with high-protein wall materials; fewer optional carrier oils for soft capsule oil suspensions compared to InnoBio.
Brand strengths: Thousand-ton annual fermentation capacity with leading domestic shipment volume of 96% high-purity beta-carotene crystals; dominant advantages in pharmaceutical raw materials and compound nutrients; complete KOSHER and HALAL certification portfolios. Mainstream models: 96% crystal raw materials, general 20% microcapsule powder. Product shortcomings: No segmented customized oil suspension or nano cold-soluble models; product range limited to standardized off-the-shelf goods, unable to match the client’s customized soft capsule and oral liquid formulas.
Brand strengths: Prominent mass production cost advantages with abundant bulk off-the-shelf inventory; low quotation for general food-grade microcapsules and oil suspensions, suitable for bulk ordinary baking and general health supplements. Mainstream models: General 20% microcapsules with maltodextrin wall material, soybean oil-based 30% oil suspension. Product shortcomings: Single wall material formulations utilizing synthetic antioxidants, failing to meet EU clean label standards and the access requirements of the client’s mid-to-high-end finished product formulas.
Combining the client’s production requirements for soft capsules, tablets and oral liquids, EU clean label compliance standards and mid-to-high-end raw material positioning, Zhejiang Medicine (lacking segmented customized dosage forms) and Shandong Tianli Pharmaceutical (formulas failing clean label standards) were eliminated. Two core supply brands – Wuhan Jiahua and Dalian InnoBio – and three mainstream models were finalized to fully match the client’s full-range production demands:
1. 20% CWS high-protein wall material microcapsule powder (tableting-specific): Compound wall material of whey protein isolate + sodium octenyl succinate starch without single maltodextrin carrier; powder angle of repose 28.5°, compatible with the client’s high-speed tablet press; uniform tablet color without delamination after 60 days of accelerated testing at 60°C with low pigment degradation, meeting shelf-life standards for high-end sustained-release tablets, covering the client’s annual 11-ton procurement demand for tableting lines.
2. 5% cold-water soluble emulsified micropowder (alternative oral liquid model): Stable mass supply for regular batches as standby raw material to supplement oral liquid production capacity during peak seasons.
30% non-GMO sunflower oil-based oil suspension (soft capsule-specific): Artificial antioxidant BHT removed, compound natural rosemary antioxidant system adopted; superior compatibility between oil and the client’s gelatin capsule shells, no soft capsule leakage after 60 days of accelerated storage at 40°C with 95.2% retained beta-carotene activity, covering the client’s annual 15-ton procurement volume for soft capsule lines.
The client’s mainstream mass production model for oral liquids selected Xi’an Haisifu’s 5% nano cold-soluble micropowder as a supplementary standby supply source for flexible small-batch restocking, with mass production relying primarily on the two core brands and three models listed above.
HiSiaddi coordinated fine-tuning of samples by the two manufacturers in accordance with the client’s internal control indicators, arranging unified pre-testing via domestic SGS laboratories before dispatching qualified samples to the client’s laboratory in the UK for re-verification. All three samples passed pilot production on the client’s line, completely resolving the three earlier production failures of oil seepage, delamination and precipitation.
The initial trial batch of the three models from the two brands totaled 4.6 tons, shipped in two consignments from Shanghai and Qingdao Ports to London Port, UK. Upon arrival, dual sampling inspection by UK customs and the client’s laboratory yielded one-time compliance of physical, microbial and compliance documents without detention or cargo hold-up. Raw materials from the selected brands boosted finished product yield from the original 70% to 95.7%, enabling the delayed new product line suspended for 45 days to officially launch on high-end pharmacies and organic supermarket shelves across the UK.
The annual order was split as follows: 15 tons of 30% oil suspension from Dalian InnoBio, 11 tons of 20% tableting microcapsules from Jiahua and 3 tons of 5% oral liquid micropowder from Jiahua, scheduled for staggered production across 10 batches. Compared with the original DSM Netherlands-sourced raw materials, overall procurement costs dropped by 27.3%, and delivery lead times were shortened from 75 days to 34 days, significantly optimizing the client’s global supply chain costs. When the client later fine-tuned trace auxiliary materials in its formulas, HiSiaddi coordinated the two manufacturers to rapidly adjust samples without charging excessive additional modification fees.
1. BRITWELL NUTRITION of the UK fully terminated raw material procurement from Dutch manufacturers and switched 100% of its 29-ton annual beta-carotene supply to domestically sourced raw materials selected by HiSiaddi. In the following year, the client added procurement demand for 1% low-irritant micropowder for children’s drops, with customized delivery coordinated by HiSiaddi via the two core brands, adding a new annual procurement order of 7.5 tons.
2. The client designated HiSiaddi as its exclusive raw material selection service provider in China, entrusting all brand evaluation and sample coordination for full carotenoid series raw materials including lutein and zeaxanthin to HiSiaddi.
3. Drawing on this neutral product selection case, HiSiaddi compiled a neutral selection database for the five domestic beta-carotene brands, forming a reference template for mid-to-high-end European and American clients, which subsequently enabled the company to secure additional procurement orders from two equivalent high-end dietary brands in Ireland and Scotland.
The five leading domestic beta-carotene manufacturers each possess distinct technical strengths, yet constrained by sales mechanisms, they universally only promote their own products and cannot provide neutral horizontal comparison data for mid-to-high-end overseas buyers. Mid-to-high-end European and American dietary brands impose highly refined raw material selection requirements subject to EU labeling, pharmacopoeia and proprietary finished product formula regulations. Reliance solely on one-sided manufacturer introductions frequently leads to model mismatch, raw material waste and delayed new product launches.
Breaking the traditional foreign trade model limited to simple supply matching and quotation transactions, HiSiaddi acts as a neutral third-party technical service provider to break information silos between competing brands, objectively dissect strengths and weaknesses of the five manufacturers and precisely match raw materials to the client’s terminal dosage form demands. This not only helps mid-to-high-end overseas clients avoid costly product selection pitfalls, smoothly complete localized substitution of imported raw materials from China and cut overall supply chain costs, but also assists leading domestic manufacturers in precisely targeting high-end overseas orders and escaping low-end homogeneous price competition, delivering long-term win-win results for both overseas buyers and domestic production manufacturers.
For inquiries about brand and model comparative analysis, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
